Member Info for Benharper

It’s looking like 2 rich, a short dose escalation one then a registrational P2. Drug could be on the market in 2 years. Might seem like a long time but in pharma terms that’s near term. Drugs take between 10-15 years to develop. It seems likely Ava6000 may get an accelerated approval at some point that may shorten these timescales

I think Tapp is already on record saying a safer Dox becomes standard of care, overnight .

In answer, curtesy of ChatGPT,to your poor attempt at fud Eggy

Lead investigators involved in clinical trials generally refrain from making public comments about the trial's results until the study is complete and the findings have been thoroughly analyzed. Premature disclosure of incomplete or interim data can be misleading and may not accurately represent the final outcome.

Once the trial is concluded, lead investigators often publish their results in scientific journals and may participate in press releases or conferences to communicate the findings to the public and the scientific community. This ensures that the information is presented accurately, in context, and has undergone the necessary peer review.

Public communication about ongoing clinical trials is typically managed carefully to maintain scientific integrity and avoid potential misconceptions or premature conclusions about a drug's efficacy and safety.

Non, give up

Come on Eggy, stay on topic, Avacta and or arthritis please. Captain Tom is straying a bit, good luck weaving that into your fud

I concur Bella, non of what’s happening is coincidence, it’s orchestrated

Ah, but is it ‘Later in Q4’?

Is it worth Chat gpting a quick CV together and winging it? Or is the matter in hand?

Either someone is working a long notice, they’ve struggled to find anyone appropriate or the job advert was part of some deal discussion brinksmanship?

The readout will give IIs concrete evidence to base any investment case on, rather than ‘It works’, ‘inflection point incoming’ etc

Thank you Hurst, for some non contrarian good old fashioned common sense.

I don’t think I or anybody needs to become a clinical trials medical officer to realise some side effects aren’t as bad as all the side effects. I mean I suppose if you were having lifestyle choice chemo, with no cancer then some side effects could be annoying but even then it would still be better than all the side effects

Fine you die happy with unblemished arthritis that’s your choice. I live having cut off a finger or five. Promising recorder playing career out the window. It’s great that we will shortly live in a world with that optionality

Yep 100% I’d go as far as chopping of the arthritic digit myself if it meant I lived

Yep those ones that don’t work at all when your dead

So chemo totally systemic or targeted to tumour and possibly to that sore bit on your knuckle. Hmm tricky choice…

TOo riGhT m ate

50 billion is achievable but probably after stunning results in the ovarian and breast cancer P2 trials have concluded and been published, I don’t think many folk think Avacta will get that far.

‘Company meets owners shocker’

BV, that’s only initially, the approach is obviously aim for the low hanging fruit. Subsequent trials can and I’m sure will run for all kinds of types of Sarcoma and other indications